AI is reshaping both diagnosis and coverage in U.S. lung cancer care. Seattle-based RevealDx has commercialized an AI-enabled software, RevealAI-Lung, that assigns a Malignancy Similarity Index to lung nodules and, in early studies, outperformed radiologists using the 1,800-word LungRads guidelines. A single click now can generate more accurate follow-up recommendations, potentially catching cancers that standard protocols miss.
Meanwhile, health insurers increasingly rely on proprietary AI systems to approve or deny treatment—most notably via prior authorization algorithms that determine "medical necessity." With only 1 in 500 denials appealed and no FDA oversight, critics warn these opaque tools can delay or withhold care, especially from chronically ill and minority patients, prompting calls for uniform regulation and independent testing.
0 comentários:
Postar um comentário